If Medicaid used the Institute for Clinical and Economic Review’s (ICER) value framework, some 42-99 percent of prescriptions for serious conditions would be at risk of not being covered, a new analysis from Xcenda suggests.
PhRMA in a blog post says those figures reveal “the dangerous effects using ICER’s value framework could have for some of the most vulnerable patients.”
According to the report almost all MS prescriptions would be affected by the transition, while 75 percent of treatments for RA, NSCLC and psoriasis “would have to be shifted to an ICER-recommended medicine.”
“ICER’s framework ignores important differences in individual patient needs and preferences, and discriminates against the elderly, the disabled and other vulnerable patients,” the blog post states.
To read the full blog post, click here.